Feline inflammatory bowel disease (IBD) and gastrointestinal lymphoma can be extremely difficult to distinguish yet require very different treatments. Accurate diagnosis is critical for welfare and outcome.
Cats with chronic GI disease suffer from persistent nausea, weight loss, discomfort, and reduced quality of life. The diagnostic journey itself causes welfare costs — repeated blood tests, ultrasounds, sedation for endoscopy or surgery for biopsy. The difficulty of distinguishing IBD from low-grade lymphoma means some cats receive empirical treatment without definitive diagnosis, which may be acceptable when biopsy carries undue anaesthetic risk in a debilitated patient. Families of cats with these diagnoses often experience significant anxiety and financial burden. Transparent communication about diagnostic uncertainty, realistic prognosis, and quality of life monitoring are essential welfare components. Palliative goals — maintaining appetite, comfort, and normal behaviour — should be central to management alongside therapeutic goals.